Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both a low baseline frequency of MDSCs and a low frequency of MDSCs in the blood of patients with melanoma following ipilimumab treatment were associated with favorable therapy outcome (134, 169-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Meyer et al., 2014
Experimental — accuracy not yet measuredIn the citing paper
“lower numbers of MDSCs in melanoma patients were associated with a better response to Ipilimumab (CTLA-4 antibody) (Meyer et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Meyer et al., 2014
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“However, autoimmune responses are also promoted, as 10–15 % of patients develop severe grade 3–4 immune-related adverse events [8].”
BackgroundInfluentialThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Recently, the fully humanized anti-CTLA-4 antibody ipilimumab was reported to increase overall survival of stage III/IV metastatic melanoma patients [8, 9].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Different malignancies favor the accumulation of different MDSC phenotypes in patients [29].”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“About 50 % of melanomas express BRAF-activating mutations [4], which are V600E and V600K substitutions in 95 % of cases [5].”
Background
Cited by
Items 401–500 of 617
Shi, G., Wang, H., & Zhuang, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3918 · Cited by 14
Tang, Y., Jiang, Q., Chen, R., Wu, S., Luo, Y., Huang, X., Yu, G., & Shao, C. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c05498 · Cited by 13
Lim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 13
Qian, F., & Han, B. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001124 · Cited by 13
Emerging mechanisms of immunotherapy resistance in sarcomas
Florou, V., & Wilky, B. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.111 · Cited by 13
NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer
Ngule, C. M., Shi, R., Ren, X., Jia, H., Oyelami, F., Li, D., Park, Y.-H., Kim, J., Hemati, H., Zhang, Y., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02102-y · Cited by 13
da Silva, I. P., Zimmer, L., Blay, J., Maio, M., Larkin, J., Grimm, M., Puri, S., Butler, M. O., Patel, S. P., Thakkar, P. K., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105833 · Cited by 13
Martinović, K. M., Vuletić, A. M., Miletić, N. T., Nedeljković, M., Babović, N. L., Matković, S., & Jurišić, V. (2023) · Innate Immunity · doi:10.1177/17534259231172079 · Cited by 13
Zou, R., Wang, Y., Ye, F., Zhang, X., Wang, M., & Cui, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02637-2 · Cited by 12
Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance
Mei, T., Ye, T., Huang, D., Xie, Y., Xue, Y., Zhou, D., Wang, W., & Chen, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01009-6 · Cited by 12
Xie, Z., Shao, J., Shen, Z., Ye, Z., Okada, Y., Okuzaki, D., Okada, N., & Tachibana, M. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03931-y · Cited by 12
Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
Silva-Romeiro, S., Flores-Campos, R., Sánchez-León, M. L., Sánchez‐Margalet, V., & de la Cruz‐Merino, L. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485642 · Cited by 12
Suh, K. J., Kim, J. W., Kim, J. E., Sung, J. H., Koh, J., Kim, K., Kim, J.-W., Ahn, S.-H., Park, D. J., Kim, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252480 · Cited by 12
Hsu, C., Chandramoorthy, H. C. K., Mohammed, J. S., Al-Hasnaawei, S., Yaqob, M., Kundlas, M., Samikan, K., Sahoo, S., Sunori, S. K., & Abbas, Z. A. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04237-4 · Cited by 11
Mechanisms of Resistance to PD-1 Checkpoint Blockade
Moser, J. C., & Hu‐Lieskovan, S. (2020) · Drugs · doi:10.1007/s40265-020-01270-7 · Cited by 11
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
Axelrod, M. L., Wang, Y., Xu, Y., Sun, X., Bejan, C. A., Ericsson, P. I. G., Nunnery, S. E., Bergman, R. E., Donaldson, J. M., Zotano, Á. G., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0023 · Cited by 11
Yadav, R., Hakobyan, N., & Wang, J. C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512502 · Cited by 11
Immuno-onco-metabolism and Therapeutic Resistance
Mir, M. A., Aisha, S., Nisar, S., Qayoom, H., & Mehraj, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_3 · Cited by 11
Barham, W. T., Stagg, M. P., Mualla, R., Dileo, M. D., & Kansara, S. G. (2025) · Cancers · doi:10.3390/cancers17010144 · Cited by 11
Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Matos, I., Barvalia, M., Chehal, M. K., Robertson, A. G., Kulić, I., Silva, J. A. F. D., Ranganathan, A., Short, A., Huang, Y., Long, E., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0278 · Cited by 11
Arrazubi, V., Goñi, S., González‐Borja, I., Hernández-García, I., Arasanz, H., Pérez‐Sanz, J., Bocanegra, A., Kochan, G. T., Escors, D., de Azúa, Y. R., et al. (2023) · Head & Neck · doi:10.1002/hed.27536 · Cited by 11
Calabrò, A., Drommi, F., Migliore, G. S., Pezzino, G., Vento, G., Freni, J., Costa, G., Cavaliere, R., Bonaccorsi, I., Sionne, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158470 · Cited by 11
Namdar, A., Mirzaei, H. R., Jadidi‐Niaragh, F., Ashourpour, M., Ajami, M., Hadjati, J., & Rezaei, A. (2015) · PubMed · doi:10.22034/iji.2015.16747 · Cited by 11
A new approach to overcoming resistance to immunotherapy: nanotechnology
Shao, J., Jin, Y. H., & Jin, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210245 · Cited by 10
Generation of Myeloid-Derived Suppressor Cells Mediated by MicroRNA-125a-5p in Melanoma
Lasser, S., Kurt, F. G. Ö., Fritz, L., Gutzeit, N., Torre, C. D. L., Altevogt, P., Utikal, J. S., & Umansky, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126693 · Cited by 10
Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer
Raza, A., Merhi, M., Relecom, A., Fernandes, Q., Inchakalody, V. P., Gul, A. R. Z., Shahab Uddin, M. S., Homsi, M. U. A., & Dermime, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96494 · Cited by 10
Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches
Flavell, R. R., Evans, M. J., Villanueva-Meyer, J. E., & Yom, S. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.025 · Cited by 10
van den Ende, T., Ezdoglian, A. A., Baas, L. M., Bakker, J., Lougheed, S. M., Harrasser, M., Waasdorp, C., Henegouwen, M. I. V. B., Hulshof, M. C. C. M., Mohammad, N. H., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2233403 · Cited by 10
Asquino, A., Cirillo, A., Strigari, L., Pace, A., Napoletano, C., Tuosto, L., Valentino, F., Ballario, A., Santini, D., Nuti, M., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03574-6 · Cited by 10
Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?
Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., & Spiliopoulou, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094393 · Cited by 9
Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma
Usta, S. Z., Uchihashi, T., Kodama, S., Kurioka, K., Inubushi, T., Shimooka, T., Sugauchi, A., Seki, S., & Tanaka, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417282 · Cited by 9
Melief, J., de Coaña, Y. P., Maas, R. R., Fennemann, F. L., Wolodarski, M., Hansson, J., & Kiessling, R. W. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02476-9 · Cited by 9
Sarkar, M., Bhuniya, A., Ghosh, S., Sarkar, A., Saha, A., Dasgupta, S., Bera, S., Chakravarti, M., Dhar, S., Guha, I., et al. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000721 · Cited by 9
Gadina, M., & O’Shea, J. J. (2024) · Science · doi:10.1126/science.adq1717 · Cited by 9
Zhou, H., Xie, Z., Morikawa, N., Sakurai, F., Mizuguchi, H., Okuzaki, D., Okada, N., & Tachibana, M. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101416 · Cited by 9
Sannicolo, S., Levra, M. G., Gouëllec, A. L., Aspord, C., Boccard, J., Chaperot, L., Toussaint, B., Moro‐Sibilot, D., Hannani, D., & Toffart, A. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2021.100845 · Cited by 8
Novel Biomarkers and Druggable Targets in Advanced Melanoma
Ferrucci, P. F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers14010081 · Cited by 8
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 8
Buj, R., Cole, A. R., Danielson, J., Xu, J. P., Hurd, D. E., Kishore, A., Kedziora, K. M., Chen, J., Yang, B., Barras, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.08.637227 · Cited by 8
Ghosh, C. C., Cournoyer, L., Liu, Y., Ballarin, A., Layman, I. B., LaPorte, J. P., Morrissey, M., Fraser, K., Perati, S., Cox, B. F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008837 · Cited by 8
Increased frequency of CD14+HLA-DR-/low cells in type 2 diabetes patients with poor glycemic control
Valtierra‐Alvarado, M. A., Castañeda‐Delgado, J. E., Lugo‐Villarino, G., Dueñas‐Arteaga, F., Rivas-Santiago, B. T., Enciso‐Moreno, J. A., & Serrano, C. J. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.011 · Cited by 8
Myeloid cell reprogramming alleviates immunosuppression and promotes clearance of metastatic lesions
Raghani, R. M., Ma, J. A., Zhang, Y., Orbach, S. M., Wang, J., Zeinali, M., Nagrath, S., Kakade, S., Xu, Q., Podojil, J. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1039993 · Cited by 7
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression
Drakes, M. L., & Stiff, P. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73359-9_3 · Cited by 7
Ahrenfeldt, J., Christensen, D. S., Østergaard, A. B., Kisistók, J., Sokač, M., & Birkbak, N. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281375 · Cited by 7
Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer
Geng, N., Hu, T., & He, C. (2022) · Biomedicines · doi:10.3390/biomedicines10123092 · Cited by 7
Unleashing the immune response against childhood solid cancers
Anderson, J. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26548 · Cited by 7
Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
Benguigui, M., Vorontsova, A., Timaner, M., Levin, S., Haj-Shomaly, J., Deo, A., Rottem, M., Manobla, B., Cooper, T. J., Raviv, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903591 · Cited by 7
Jin, Y., Ide, H., Nagata, M., Kobayashi, T., Lu, J., Ikehata, Y., Shimizu, F., Lü, Y., & Horie, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641383 · Cited by 7
A role for Follistatin-like protein 1 (FSTL1) in colorectal cancer
Voutsadakis, I. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.112 · Cited by 7
Chen, D., Wu, R., Liu, Z., Wei, Y., & Kuang, D. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004035 · Cited by 6
Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond
Höchst, B., & Knolle, P. A. (2017) · ORL · doi:10.1159/000455810 · Cited by 6
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
Fan, F., Dong, G., Han, C., Ding, W., Li, X., Dong, X., Wang, Z., Liang, P., & Yu, J. (2023) · International Journal of Hyperthermia · doi:10.1080/02656736.2023.2172219 · Cited by 6
Immune signatures predicting responses to immunomodulatory antibody therapy
Pawelec, G. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.003 · Cited by 6
Mechanism of Action and Pharmacologic Features of Drugs Targeting PD ‐1/ PDL ‐1 and CTLA ‐4
Rodriguez, M., Bucktrout, R., Orlando, A., Serganova, I. S., & Zappasodi, R. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch11 · Cited by 6
Witte, H. M., Gebauer, N., & Steinestel, K. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103592 · Cited by 6
Singh, P., SOUZA, P. D., Scott, K. F., Hall, B. M., Verma, N. D., Becker, T. M., Toh, J. W. T., Sajinovic, M., & Spring, K. J. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0032-9 · Cited by 6
Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
Shibata, Y., Kishida, T., Kouro, T., Wei, F., Igarashi, Y., Himuro, H., Noguchi, T., Koizumi, M., Suzuki, T., Osaka, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1269935 · Cited by 6
Immune therapy in colorectal cancer
Lapeyre-Prost, A., Terme, M., Pernot, S., Marcheteau, E., Pointet, A., Voron, T., Tartour, É., & Taïeb, J. (2017) · Colorectal Cancer · doi:10.2217/crc-2017-0002 · Cited by 6
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016
Gulley, J. L., Repasky, E. A., Wood, L. S., & Butterfield, L. H. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0262-1 · Cited by 6
Tandarić, L., Auranen, A., Kleinmanns, K., Christensen, R. D., Thomsen, L. C. V., Wogsland, C. E., McCormack, E., Maenpaa, J. U., Madsen, K., Petersson, K. S., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13811 · Cited by 6
Mechanisms of Immune Evasion by Cancer
Rotte, A., & Bhandaru, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-48066-4_8 · Cited by 6
Nanotechnology and Immunomodulators in Cancer
Volovat, C. D., Volovăț, S. R., & Agop, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-6379-6_5 · Cited by 5
Pourmir, I., Gazeau, B., Basile, H. D. S., & Fabre, E. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.14 · Cited by 5
Methods for the Detection of Circulating Biomarkers in Cancer Patients
Mondelo‐Macía, P., Rodríguez‐Ces, A. M., Suárez‐Cunqueiro, M. M., & Muinelo‐Romay, L. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-04039-9_21 · Cited by 5
MYO1F in neutrophils is required for the response to immune checkpoint blockade therapy
Qu, Y., Liang, W., Yu, M., Wang, C., Luo, M., Zhong, L., Li, Z., & Wang, F. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241957 · Cited by 5
Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues
Kokolus, K. M., Obermajer, N., & Kaliński, P. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.041 · Cited by 5
Innate and Adaptive Immune Responses to Cancer
Rausch, M. P., & Hastings, K. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_5 · Cited by 5
Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
Mannah, B., Park, J., & Lim, S. Y. (2025) · International Journal of Cancer · doi:10.1002/ijc.35477 · Cited by 5
A Career in Lung Cancer: Pushing Beyond Chemotherapy
Patil, P. D., Shepherd, F. A., & Johnson, D. H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239397 · Cited by 5
Makita, K., Hamamoto, Y., Kanzaki, H., Nagasaki, K., Matsuki, H., Inoue, K., & Kozuki, T. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100795 · Cited by 5
Exosome, an important transmitter in the drug resistance of non-small cell lung cancer
Ji, H., Zhang, L., & Ye, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1539047 · Cited by 4
Immunotherapy and predictive immunologic profile: the tip of the iceberg
Pereira, T. C., Rodrigues‐Santos, P., Almeida, J. S., Salgueiro, F. R., Monteiro, A. R., Macedo, F., Soares, R. F., Domingues, I., Jacinto, P., & Sousa, G. (2021) · Medical Oncology · doi:10.1007/s12032-021-01497-8 · Cited by 4
Role of myeloid cells in the tumor microenvironment
Balakrishnan, A., Vig, M., & Dubey, S. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.33 · Cited by 4
Kim, Y., Choi, C., Park, J. H., Ahn, W.-G., Shin, S.-W., Kim, S., & Noh, J. M. (2022) · Radiation Oncology Journal · doi:10.3857/roj.2021.00885 · Cited by 4
Distinct Roles of Monocyte Subsets in Cancer
Cortez, M. A. S., Eilenberg, W. H., Neumayer, C., & Brostjan, C. (2025) · Cells · doi:10.3390/cells14241982 · Cited by 4
The Immune Landscape in Women Cancers
Timperi, E., Vissio, E., Marchiò, C., & Romano, E. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_8 · Cited by 4
Self-citationЗаботина, Т. Н., Panchuk, I., Tabakov, D., & Захарова, Е. Н. (2020) · Practical oncology · doi:10.31917/2103249 · Cited by 4
Ma, J., Dong, J., & Ji, X. (2018) · Glioma · doi:10.4103/glioma.glioma_2_17 · Cited by 4
Cancer immunotherapy by silencing transcription factor c-Rel using peptide-based nanoparticles
Lang, S., Zhu, Y., Tan, Z., Zhang, Y. X., Liang, R., Ren, J., Li, P., Pan, F., Cai, L., & Chen, Y. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1554496 · Cited by 4
Chen, Y., Wang, Y., Jin, L., Chen, B., Zhang, X., Chang, L., Hu, Z., Wang, Y., & Lu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364924 · Cited by 3
Tang, R., Juan, Z., Xing, F., Yi, Z., & Fu, Y. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112452 · Cited by 3
Liu, X., Liu, S., Jiang, Z., Yang, C., Yang, X., Li, J., & Liu, H. (2023) · Immunotherapy · doi:10.2217/imt-2023-0105 · Cited by 3
Zhang, X.-M., Zhao, F.-Y., Gao, L.-F., Xu, T., Yang, F., & Qian, N. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i12.110351 · Cited by 3
Innate and Adaptive Immune Responses to Cancer
Hastings, K. T., & Rausch, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_4 · Cited by 3
Biology of Myeloid-Derived Suppressor Cells
Alicea-Torres, K. M., & Gabrilovich, D. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_10 · Cited by 3
Modelling the metastatic immune microenvironment in triple-negative breast cancer
de la Fuente, L. R., Law, A. M. K., Rangel-Sanchez, L., Venhuizen, J., Steffan, F., Castillo, L. E., Anderson, R. L., Valdés‐Mora, F., & Gallego‐Ortega, D. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02186-4 · Cited by 3
Cannabidivarin directly targets the immunosuppressive activity of regulatory myeloid cells in tumors
Steinberg, M., Wyrobnik, I., Procaccia, S., Rosenblum, R., Gelfand, A., Avisidris, S., Novak‐Kotzer, H., & Meiri, D. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118697 · Cited by 3
The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact
Hajjar, J., Stephen, B., Aaroe, A., Aiche, M. M., Al-Zubidi, N. S., Ameri, M., Brooks, K. A., Carabenciov, I. D., Chambers, M. S., Chaudhry, A. L., et al. (2026) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-26-12 · Cited by 3
Neagu, M. T., & Constantin, C. (2015) · InTech eBooks · doi:10.5772/59494 · Cited by 3
Auphan‐Anezin, N., & Schmitt‐Verhulst, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201445300 · Cited by 3
Lipid peroxidation and superoxide dismutase activity in pea seedlings under clinorotation.
Бараненко, В. В. (1998) · PubMed · Cited by 2
Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments
Rayes, T. E., Gao, D., Altorki, N. K., Cox, T. R., Erler, J. T., & Mittal, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_13 · Cited by 2
Cody, J. W., Ellis-Connell, A. L., O’Connor, S. L., & Pienaar, E. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011425 · Cited by 2
Age‐Related Changes in Myeloid Cells and Their Impact on Subcutaneous Melanoma Growth in Mice
Landreth, K. M., Thomas, D. D., Nohoesu, R., Basnet, A., Damron, F. H., Garland‐Kledzik, M., Sen-Kilic, E., & Liu, T. W. B. (2025) · Aging and Cancer · doi:10.1002/aac2.70006 · Cited by 2
Zhu, Y., Ning, Z., Deng, Y., Huang, C., Li, H., Sun, Y., & Meng, Z. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70145 · Cited by 2
Muhammad, S. N., Zakkariya, Z. T., Shaji, S., Sunilkumar, A. K., George, A., Radhakrishnan, S. P., Nair, S. V., & Koyakutty, M. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500120 · Cited by 2
Galectin-8 is a major ligand of LILRB4 prompting MDSC functions in the tumor microenvironmentPreprint
Wang, Y., Sun, Y., Deng, S., Song, T., Wang, Y., & Xu, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.27.501694 · Cited by 2
Zhuang, Y., Chen, J., Mai, Z., Huang, W., & Zhong, W. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02216-4 · Cited by 2
Національний інститут раку, К., Храновська, Н. М., Скачкова, О. В., Національний інститут раку, К., Gorbach, O. I., Національний інститут раку, К., Жукова, В. М., Національний інститут раку, К., Glavatskyi, O., ДУ «Інститут нейрохірургії ім. акад. А.П. Ромоданова НАМН України», К., et al. (2019) · Clinical Oncology · doi:10.32471/clinicaloncology.2663-466x.38.22510 · Cited by 2
Metadata
- Authors
- Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Speiser, Daniel E.
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 247-257
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029062
- OpenAlex
- W2080886891
- Cited by
- 560
- References
- 58
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 29 · 2023: 59 · 2022: 64 · 2021: 73 · 2020: 85 · 2019: 49 · 2018: 36 · 2017: 36 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (141879, 135553, 310030)
- Fondation ISREC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- myeloid-derived suppressor cells, metastatic melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, treatment response, monocytic MDSCs, tumor resection, lactate dehydrogenase, immune monitoring
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms, Treatment Outcome, Lipopolysaccharide Receptors, Myeloid Cells, Biomarkers, Pharmacological, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.